Drug updated on 10/29/2024
| Dosage Form | Tablet (oral; 250 mg) |
| Drug Class | Antihelmintics |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of fascioliasis in patients 6 years of age and older.
Latest News
Summary
- This summary is based on the review of one randomized controlled trial(s). [1]
- The study does not provide data on the effectiveness of triclabendazole in treating human fascioliasis.
- The study population consisted of 45 healthy participants, with no reported subgroup analyses or outcomes specific to effectiveness.
- Triclabendazole showed a mean placebo-corrected QTcF prolongation of 9.2 ms at the therapeutic dose and 21.7 ms at the supratherapeutic dose, with the upper limit of the two-sided 90% confidence interval exceeding 10 ms at most timepoints, indicating a potential effect on cardiac repolarization.
- No deaths, serious adverse events, study discontinuations, or clinically relevant abnormalities in laboratory evaluations and vital signs were observed in the 45 healthy participants.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Egaten (triclabendazole) Prescribing Information. | 2022 | Novartis Pharmaceuticals Corporation, East Hanover, NJ |
Randomized Controlled Trials
| Document Title | Sex Distribution | Year | Source |
|---|---|---|---|
| Effects of triclabendazole and its metabolite exposure on the heart-rate-corrected QT intervals: A randomized, placebo- and positive-controlled thorough QT study in healthy individuals | 45Subjects F: 20% M: 80% | 2023 | Clinical and Translational Science |
Sex Distribution:
F:20%
M:80%
45Subjects
Year:
2023
Source:Clinical and Translational Science